A subsequent randomized clinical trial using CXCR2 antagonist AZD5069 as add on therapy for patient with severe asthma demonstrated no significant difference in frequency of exacerbations though it was limited by the overall low exacerbation rate [74]. Here, CXCR2 is linked to asthma.